Brief: Ascletis Pharma Says ASC47 Showed Greater Efficacy With Tirzepatide
13/08/2025 02:42
Aug 13 (Reuters) - Ascletis Pharma Inc 1672.HK: ANNOUNCES ASC47 SHOWS GREATER EFFICACY WITH TIRZEPATIDE ASC47 AND TIRZEPATIDE COMBINATION SHOWS 87% GREATER WEIGHT REDUCTION Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026